Skip to main content
Discover what's not being covered
Get Started
SubscribeLogin
Published • loading... • Updated

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate ...

Summary by Hastings Tribune
AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone The trial will continue to evaluate the second dual primary endpoint…

11 Articles

Seeking AlphaSeeking Alpha
Lean Right

BioNTech falls as mRNA therapy for head and neck cancer fails in mid-stage trial

BioNTech (BNTX) drops after BNT113 + Keytruda trial misses PFS endpoint in HPV16+ head & neck cancer. Read more here.

·Ra'anana, Israel
Read Full Article
BloombergBloomberg
Center

BioNTech Says Cancer Treatment Didn't Help in Early Analysis

·New York, United States
Read Full Article
ReutersReuters
+3 Reposted by 3 other sources
Center

BioNTech's mRNA cancer therapy misses first goal in head and neck trial

·London, United Kingdom
Read Full Article
HandelsblattHandelsblatt
Lean Right

Biotech: Setback for Biontech – Cancer Therapy Failed

In the case of head and neck cancer, mRNA immunotherapy did not stop the disease from progressing. Nevertheless, the Mainzians do not see a definitive outcome.

·Düsseldorf, Germany
Read Full Article
biopharmadive.combiopharmadive.com
Center

BioNTech mRNA cancer immunotherapy misses first objective in key study

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.

Read Full Article
Hastings TribuneHastings Tribune
Center

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate ...

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone The trial will continue to evaluate the second dual primary endpoint…

·Nebraska, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in Nebraska, United States on Tuesday, October 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Cancer icon

Cancer

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal